Abstract

An orphan disease is characterized by its rarity, leading to a lack of interest from pharmaceutical industries and medical researchers due to limited financial viability. Consequently, the etiopathology and causative agents of such diseases remain unidentified, and specific drug therapies are unavailable. Treatment relies on the clinical experience and intuition of individual physicians, with no standardized protocol or sufficient patient data for validation. Toxic Epidermal Necrolysis (TEN) is one such orphan disease, with an incidence of 1 to 1.5 per million. It often results from severe hypersensitivity reactions to drugs or infections, causing the immune system to destroy the epidermal layer, leading to multiorgan failure and a high mortality rate. This case highlights the complexities and controversies in managing TEN. Despite numerous specialists' involvement, her treatment led to a legal battle, culminating in a significant compensation award due to alleged medical negligence.

• 1.   Nix, Alexander.Alexander Nix - Success has many fathers and failure is an... (brainyquote.com)Link Last accessed on 9th July 2024. https://www. brainyquote.com/quotes/alexander_nix_1038761.
• 2.   orphan | Search Online Etymology Dictionary (etymonline.com) Link Last accessed on 9th July 2024. https://www.etymonline.com/ search?q=orphan.
• 3.   Creamer D, Walsh SA, Dziewulski P, et al. UK guidelines for the management of StevensJohnson syndrome/toxic epidermal necrolysis in adults 2016. British Journal of Dermatology; 174(6):1194–1227.
• 4.   Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, Shear NH. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Update. Am J Clin Dermatol. 2015;16(6):475-493.
• 5.   Roujeau JC, Guillaume JC, Fabre JP, Penso D, Flechet ML, Girre JP. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981–1985. Arch Dermatol 1990;126:37–42.
• 6.   Chan HL, Stern RS, Arndt KA, Arndt KA, Langlois J, Jick SS, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990;126:43–7.
• 7.   Yang MS, Lee JY, Kim J, Kim GW, Kim BK, Kim JY, Park HW, Cho SH, Min KU, Kang HR. Incidence of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Nationwide Population-Based Study Using National Health Insurance Database in Korea. PLoS One. 2016 Nov 11;11(11):e0165933.
• 8.   Chan HL, Stern RS, Arndt KA, Arndt KA, Langlois J, Jick SS, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990;126:43–7.
• 9.   Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, StevensJohnson syndrome, and erythema multiforme. Arch Dermatol. 1993 Jan;129(1):92-6.
• 10.   Abe R. Immunological response in StevensJohnson syndrome and toxic epidermal necrolysis. J Dermatol. 2015;42(1):42-48.
• 11.   LYELL A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol. 1956 Nov;68(11):355-61.
• 12.   Pejčić AV. Stevens-Johnson syndrome and toxic epidermal necrolysis associated with the use of macrolide antibiotics: a review of published cases. Int J Dermatol. 2021 Jan;60(1):12-24.
• 13.   Moshfeghi M, Mandler HD. Ciprofloxacininduced toxic epidermal necrolysis. Ann Pharmacother. 1993 Dec;27(12):1467-9.
• 14.   Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A. StevensJohnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008 Jan;128(1):35-44.
• 15.   Kunal Saha (Dr.) V Sukumar Mukherjee (Dr.) 2006 (2) CPR 14:2006 (3) CPJ 142 (NCDRC).
• 16.   Koley, Tapas K. Medical Negligence and the Law in India: Duties, Responsibilities and rights. Oxford University Press. 2010. Defining Professional Negligence, p24-26.
• 17.   Kannan, K. Modi’s Medical Jurisprudence & Toxicology. 27th Ed. LexisNexis. 2022.
• 18.   Kabra, SG. Perverse Medical Negligence Judgments are the Bane of Medical Profession. Antara Infomedia Publications. 2023.
• 19.   Ting H.C., Adam, B.A., Stevens-Johnson Syndrome: A Review of 34 Cases. International Journal of Dermatology. Volume 24, Issue1, January 1985, Pages 587-591.
• 20.   Allen, Ronald J. and Alex Stein, 2013, “Evidence, Probability and the Burden of Proof”, Arizona Law Journal, 55(3): 557–602.
• 21.   Koffa, K. (1935): Principles of Gestalt Psychology. London, Routledge & Kegan Paul Ltd.Law Of Proximity (Gestalt Principle).
• 22.   Tran TH, Lan PT, Khang TH, Luong VH. Systemic Corticosteroid Therapy for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Vietnam: Clinical Evaluation and Analysis of Serum Cytokines. Open Access Maced J Med Sci. 2022 Jan 16; 10(B):303-308.
• 23.   Gaddis, William. A Frolic of His Own.Poseidon Press, 1994.
• 24.   Joel v Morison [1834] EWHC KB J39.
• 25.   Section 106, Bharatiya Nyaya Sanhita (BNS) 2023.
• 26.   National Medical Commission (NMC) Act, 2019.

Data Sharing Statement

Funding